Troponins may be useful guide for ARNI therapy in HFpEF, finds JACC study

Written By :  dr. Abhimanyu Uppal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-07-24 04:51 GMT   |   Update On 2021-07-24 04:51 GMT
Advertisement

Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for one-half of HF cases, and research has been ongoing for many years to find effective treatment strategies for the same. The prognostic value of high sensitivity troponin-T (hs-TnT) in HFpEF, and whether hs-Tn modifies the treatment response to sacubitril/valsartan, remains uncertain.

In this regard, Gori et al assessed the relationship among hs-TnT, outcomes, and the efficacy of treatment with sacubitril/valsartan in the PARAGON-HF trial and found that higher hs-TnT was associated with increased risk outcomes in HFpEF which were reduced with the use of sacubitril/valsartan compared with valsartan.

Advertisement

In the PARAGON-HF trial, sacubitril/ valsartan resulted in modest reductions in total HF hospitalizations (HHF) and cardiovascular death (CVD) compared with valsartan alone. Since the early studies of high-sensitivity troponins in chronic heart failure with reduced ejection fraction (HFrEF), the predictive value of troponin became increasingly evident.

Gori et al thus aimed to explore the utility of this marker in HFpEF from the PARAGON-HF cohort and compared the risk of the composite outcome of CVD and total HHF according to hs-TnT. They also assessed the effect of allocated treatment on hs-TnT.

The study has provided following important findings:

1. Female sex is strongly associated with lower hsTnT. This trend is not evident for NT-proBNP.

2. Conversely, hsTnT is unaffected by high body mass index while NT-proBNP and BNP concentrations are significantly lower in obese.

3. Sacubitril/valsartan decreased NT-proBNP concentrations over 16 weeks by 19%, while the decrease in hsTnT was 9%.

4. Sacubitril/valsartan reduced circulating NT-proBNP levels to a lesser extent in patients with atrial fibrillation (AF), but the same unexpected trend was not reported for hsTnT.

5. Also, antecedent AF raised NT-proBNP while no such interaction occurred with hsTnT.

6. Consistent with the overall lack of superiority of sacubitril/valsartan versus valsartan in PARAGON-HF, NT-proBNP baseline concentrations did not affect the impact of the study drug.

7. However, sacubitril/valsartan tended to have a greater effect in patients with higher baseline hsTnT than in those with lower baseline hsTnT.

"Altogether, we can conclude that the 2 cardiac biomarkers tell somewhat different stories in HFpEF", mention Latini et al in an accompanying editorial. In other words, a complementary relationship between natriuretic peptides and hsTnT has been confirmed so that the combination of the 2 biomarkers is proposed for identification of patients with HFpEF at high risk.

To conclude, higher baseline hs-TnT was associated with increased risk of CVD/HHF, whereas hs-TnT decrease at 16 weeks led to lower subsequent risk of CVD/HHF compared with those who had persistently elevated values. Sacubitril/ valsartan significantly reduced hs-TnT compared with valsartan. hs-TnT may be helpful in identifying patients with HFpEF who are more likely to benefit from sacubitril/valsartan.

Source: JACC Heart Failure: https://doi.org/10.1016/j.jchf.2021.04.009


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News